Delores B. emails, "So grateful for positive, informative article on Amarin. Thank you, thank you."
Back to Dendreon, BertBean6 asks, "Where did the Victrelis royalty come from and is this a good thing for Dendreon?"
The Victrelis royalty certainly came out of the blue, didn't it? Dendreon booked about $3 million in royalty revenue during the September quarter based off sales of Merck's (MRK) hepatitis C drug Victrelis. The royalty rate appears to be in the single digits.
Oddly, Dendreon has never before discussed a Victrelis royalty, but it's origin stems from Dendreon's acquisition of Corvas in 2003. Prior to that, Corvas had entered into a hepatitis C drug development pact with Schering-Plough (now Merck.) Corvas, now Dendreon is on the core patent covering Victrelis.Deutsche Bank biotech analyst Robyn Karnauskas estimates the Victrelis royalty stream to be worth 64 cents per share in her Dendreon discounted cash flow model. I've seen other estimates valuing the Victrelis royalty at $1.50 to $2 per share. --Written by Adam Feuerstein in Boston.
>To contact the writer of this article, click here: Adam Feuerstein. >To follow the writer on Twitter, go to http://twitter.com/adamfeuerstein. >To submit a news tip, send an email to: firstname.lastname@example.org. Follow TheStreet on Twitter and become a fan on Facebook.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV